Become part of a
success story.

SPL Medical is a young medical research and development company that has already successfully developed new technologies in the field of MRI contrast agents. SPL Medical's first project turns the diagnostic world upside-down: Ferrotran®. This innovative Gadolinium-free contrast agent is more reliable in the early detection of metastases in prostate cancer than any product currently available on the market and also offers the highest potential for other indications.

Reasons to
Invest in Ferrotran®.

THE LEADING GADOLINIUM-FREE CONTRAST AGENT.


After a successful phase III study, Ferrotran® aims to become market leader.

HIGH PROBABILITY OF MARKET APPROVAL


Additionally supported by published data on multiple sclerosis, angiography and prostate cancer.

EU MARKET ENTRY
IS IMMINENT.


First launch in Germany, followed by the DACH region.

STRONG GLOBAL
GROWTH.


in the MRI contrast agent market by the end of 2024, with EU and US as the largest markets.

MILLION EXPECTED SALES BY THE END OF 2030.


Ferrotran® will noticeably revolutionize the market.

LONG-TERM SECURED PATENT PROTECTION.


The uniqueness of Ferrotran® will remain protected until 2039.

Contact now